McDonald Cameron, Bauer Judy, Capra Sandra, Coll Joseph
Centre for Dietetics Research, University of Queensland, Brisbane, Australia.
BMC Cancer. 2014 Apr 16;14:264. doi: 10.1186/1471-2407-14-264.
Loss of lean body mass (LBM) is a common occurrence after treatment for breast cancer and is related to deleterious metabolic health outcomes [Clin Oncol, 22(4):281-288, 2010; Appl Physiol Nutr Metab, 34(5):950-956, 2009]. The aim of this research is to determine the effectiveness of long chain omega-3 fatty acids (LCn-3s) and exercise training alone, or in combination, in addressing LBM loss in breast cancer survivors.
METHODS/DESIGN: A total of 153 women who have completed treatment for breast cancer in the last 12 months, with a Body Mass Index (BMI) of 20 to 35 kg/m2, will be randomly assigned to one of 3 groups: 3g/d LCn-3s (N-3), a 12-week nutrition and exercise education program plus olive oil (P-LC) or the education program plus LCn-3s (EX+N-3). Participants randomised to the education groups will be blinded to treatment, and will receive either olive oil placebo (OO+N-3) or LCn-3 provision, while the N-3 group will be open label. The education program includes nine 60-75 min sessions over 12 weeks that will involve breast cancer specific healthy eating advice, plus a supervised exercise session run as a resistance exercise circuit. They will also be advised to conduct the resistance training and aerobic training 5 to 7 days per week collectively. Outcome measures will be taken at baseline, 12-weeks and 24-weeks. The primary outcome is % change in LBM as measured by the air displacement plethysmograhy. Secondary outcomes include quality of life (FACT-B + 4) and inflammation (C-Reactive protein: CRP). Additional measures taken will be erythrocyte fatty acid analysis, fatigue, physical activity, menopausal symptoms, dietary intake, joint pain and function indices.
This research will provide the first insight into the efficacy of LCn-3s alone or in combination with exercise in breast cancer survivors with regards to LBM and quality of life. In addition, this study is designed to improve evidence-based dietetic practice, and how specific dietary prescription may link with appropriate exercise interventions.
ACTRN12610001005044; and World Health Organisation Universal trial number: U1111-1116-8520.
瘦体重(LBM)流失是乳腺癌治疗后常见的现象,且与不良的代谢健康结果相关[《临床肿瘤学》,22(4):281 - 288,2010;《应用生理学与营养代谢》,34(5):950 - 956,2009]。本研究的目的是确定长链ω-3脂肪酸(LCn-3s)、运动训练单独或联合使用在解决乳腺癌幸存者LBM流失方面的有效性。
方法/设计:总共153名在过去12个月内完成乳腺癌治疗、体重指数(BMI)为20至35 kg/m²的女性将被随机分配到3组中的一组:每天3克LCn-3s(N-3)组、一个为期12周的营养与运动教育项目加橄榄油组(P-LC)或教育项目加LCn-3s组(EX+N-3)。被随机分配到教育组的参与者对治疗方案不知情,将接受橄榄油安慰剂(OO+N-3)或LCn-3补充剂,而N-3组将采用开放标签。教育项目包括在12周内进行九次60 - 75分钟的课程,内容将涉及针对乳腺癌患者的健康饮食建议,以及一次作为抗阻运动循环的监督运动课程。还将建议他们每周总共进行5至7天的抗阻训练和有氧训练。将在基线、12周和24周时进行结果测量。主要结果是通过空气置换体积描记法测量的LBM百分比变化。次要结果包括生活质量(FACT-B + 4)和炎症(C反应蛋白:CRP)。还将进行红细胞脂肪酸分析、疲劳、身体活动、更年期症状、饮食摄入、关节疼痛和功能指标等额外测量。
本研究将首次深入了解LCn-3s单独或与运动联合使用对乳腺癌幸存者LBM和生活质量的疗效。此外,本研究旨在改进基于证据的饮食实践,以及特定饮食处方如何与适当的运动干预相联系。
ACTRN12610001005044;以及世界卫生组织通用试验编号:U1111 - 1116 - 8520。